The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
I frequently use Cognitive Behavioral Therapy in my practice. I help individuals and couples break free from anxiety, overwhelm, and emotional exhaustion so they can reconnect with themselves and each ...
My practice is safe to work in-person and through telehealth, whichever you prefer. We are all alive and trying to learn something about living; we live the way that we feel. We do this automatically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results